Brief: Corcept Completes Enrollment In Phase 3 Gradient Trial Of Relacorilant In Patients With Adrenal Cushing’s Syndrome

Corcept Therapeutics Incorporated

01/04/2024 16:00

April 1 (Reuters) - Corcept Therapeutics Inc  CORT.O :
    * CORCEPT COMPLETES ENROLLMENT IN PHASE 3 GRADIENT TRIAL OF
RELACORILANT IN PATIENTS WITH ADRENAL CUSHING’S SYNDROME

Source text for Eikon:  ID:nGNX1lbprV 
Further company coverage:  CORT.O 

 ((Reuters.Briefs@thomsonreuters.com;))